KisterI. Disease-modifying therapies can be safely discontinued in an individual with stable relapsing remitting MS—Yes. Mult Scler2017: 23(9): 1188–1090.
2.
TobinWOWeinshenkerB. Disease-modifying therapies can be safely discontinued in an individual with stable relapsing remitting MS—No. Mult Scler2017: 23(9): 1188–1090.
3.
TortorellaCBellacosaAPaolicelliD. Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis. J Neurol Sci2005; 239(1): 1190–1192.
4.
TremlettHZhaoYJosephJ. Relapses in multiple sclerosis are age- and time-dependent. J Neurol Neurosurg Psychiatry2008; 79(12): 1368–1374.
5.
SignoriASchiavettiIGalloF. Subgroups of multiple sclerosis patients with larger treatment benefits: A meta-analysis of randomized trials. Eur J Neurol2015; 22(6): 960–966.
6.
FagiusJFeresiadouALarssonEM. Discontinuation of disease modifying treatments in middle aged multiple sclerosis patients. First line drugs vs natalizumab. Mult Scler Relat Disord2017; 12: 82–87.
7.
BonenfantJBajeuxEDeburghgraeveV. Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis?Eur J Neurol2017; 24(2): 237–244.
8.
BirnbaumG.Stopping disease-modifying therapy in nonrelapsing multiple sclerosis: Experience from a clinical practice. Int J MS Care2017; 19(1): 11–14.
9.
BstehGFeigeJEhlingR. Discontinuation of disease-modifying therapies in multiple sclerosis—Clinical outcome and prognostic factors. Mult Scler. 2017; 23(9): 1241–1248.
10.
KisterISpelmanTAlroughaniR. Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: A propensity score-matched study. J Neurol Neurosurg Psychiatry2016; 87(10): 1133–1137.
11.
TobinWOWeinshenkerBG.Stopping immunomodulatory medications in MS: Frequency, reasons and consequences. Mult Scler Relat Disord2015; 4(5): 437–443.
